Ignite Creation Date:
2025-12-24 @ 11:29 PM
Ignite Modification Date:
2026-01-04 @ 8:57 PM
Study NCT ID:
NCT03361956
Status:
COMPLETED
Last Update Posted:
2022-11-17
First Post:
2017-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Romania'], 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2022-10-03', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D006509', 'term': 'Hepatitis B'}], 'ancestors': [{'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D018347', 'term': 'Hepadnaviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000716080', 'term': 'JNJ-56136379'}, {'id': 'D012964', 'term': 'Sodium'}, {'id': 'C413685', 'term': 'entecavir'}], 'ancestors': [{'id': 'D008672', 'term': 'Metals, Alkali'}, {'id': 'D004602', 'term': 'Elements'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D019565', 'term': 'Metals, Light'}, {'id': 'D008670', 'term': 'Metals'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrialDisclosure@its.jnj.com', 'phone': '844-434-4210', 'title': 'Senior Director', 'organization': 'Janssen Sciences Ireland UC'}, 'certainAgreement': {'otherDetails': 'If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will with hold such publication for up to an additional 60 days.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From screening to end of study (up to Week 80) (Screening period of 8 weeks + Initial treatment phase of 24 weeks [Week 0 to Week 24] + 24 week Follow-up [Week 0 to Week 48], and Treatment extension phase of 24 weeks [Week 24 to Week 48] + 24 week follow-up [Week 24 to Week 72]= Week 80)', 'description': 'Safety analysis set included all participants who received at least one dose of the study agent and all safety endpoints analyzed by the treatment arm as treated.', 'eventGroups': [{'id': 'EG000', 'title': 'Initial Treatment Phase: Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who did not participate in the treatment extension phase after Week 24 were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.", 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 9, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Initial Treatment Phase: Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who did not participate in the treatment extension phase after Week 24 were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 28, 'deathsNumAtRisk': 28, 'otherNumAffected': 18, 'seriousNumAtRisk': 28, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Initial Treatment Phase: Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who did not participate in the treatment extension phase after Week 24 were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 66, 'deathsNumAtRisk': 66, 'otherNumAffected': 19, 'seriousNumAtRisk': 66, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Initial Treatment Phase: Part B: JNJ-56136379 250 mg (Open-label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who did not participate in the treatment extension phase after Week 24 were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 32, 'deathsNumAtRisk': 32, 'otherNumAffected': 12, 'seriousNumAtRisk': 32, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Initial Treatment Phase: Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who did not participate in the treatment extension phase after Week 24 were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 63, 'deathsNumAtRisk': 63, 'otherNumAffected': 11, 'seriousNumAtRisk': 63, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG005', 'title': 'Treatment Extension Phase: Parts A and B: Pooled Placebo + NA', 'description': 'Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 33, 'deathsNumAtRisk': 33, 'otherNumAffected': 25, 'seriousNumAtRisk': 33, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'Treatment Extension Phase: Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75mg from Week 24 to Week 48 in the treatment extension phase. Participants who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Treatment Extension Phase: Part A: JNJ-56136379 75 mg + NA', 'description': 'Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 38, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 4}, {'id': 'EG008', 'title': 'Treatment Extension Phase: Part B: JNJ-56136379 250 mg (Open-label)', 'description': 'Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 15, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Treatment Extension Phase: Part B: JNJ-56136379 250 mg + NA', 'description': 'Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.', 'otherNumAtRisk': 48, 'deathsNumAtRisk': 48, 'otherNumAffected': 42, 'seriousNumAtRisk': 48, 'deathsNumAffected': 0, 'seriousNumAffected': 3}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Iron Deficiency Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Neutrophilia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Atrioventricular Block First Degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Atrioventricular Block Second Degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Bundle Branch Block Right', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Defect Conduction Intraventricular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Palpitations', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ear Congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Motion Sickness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Tinnitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Tympanic Membrane Perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Goitre', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cataract', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Conjunctivitis Allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dry Eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Swelling of Eyelid', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Xerophthalmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abdominal Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abdominal Distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abdominal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abdominal Pain Lower', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abdominal Pain Upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abdominal Tenderness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Chronic Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dental Caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dry Mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Duodenal Ulcer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Duodenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Epigastric Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Eructation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Faeces Hard', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gastrooesophageal Reflux Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gingival Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Glossodynia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Haemorrhoidal Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Haemorrhoids', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hiatus Hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hypoaesthesia Oral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Mouth Ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Odynophagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Periodontal Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Tongue Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Tooth Impacted', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Toothache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Chest Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 4}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Influenza Like Illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Malaise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Non-Cardiac Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Thirst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gallbladder Polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hepatic Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hepatic Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hepatic Steatosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hyperbilirubinaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ocular Icterus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Seasonal Allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Alveolar Osteitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Asymptomatic Bacteriuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Bronchitis Viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ear Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Folliculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Furuncle', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Helicobacter Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hepatitis B', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Herpes Virus Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Laryngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Laryngitis Viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Localised Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 7}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 8}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Periodontitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pharyngitis Streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pulpitis Dental', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Suspected Covid-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Tooth Abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 8}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urinary Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Vaginal Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Viral Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Viral Tracheitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Viral Upper Respiratory Tract Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Vulvitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Arthropod Bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Corneal Abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Eye Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Gingival Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Joint Injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ligament Sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Muscle Strain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Skin Abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Skin Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Wound', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Alanine Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Amylase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Aspartate Aminotransferase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Bilirubin Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Calcium Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Cholesterol Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Creatine Phosphokinase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Creatinine Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Glucose Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Magnesium Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Potassium Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Triglycerides', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Blood Triglycerides Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Electrocardiogram QT Prolonged', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Electrocardiogram T Wave Inversion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Glomerular Filtration Rate Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hepatic Enzyme Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hepatitis B Dna Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Lipase Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Protein Urine Present', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Sars-Cov-2 Test Positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ultrasound Liver Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urinary Sediment Present', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urine Analysis Abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urine Leukocyte Esterase Positive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Weight Decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abnormal Loss of Weight', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Decreased Appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Diabetes Mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Glucose Tolerance Impaired', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hyperkalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hyperphosphataemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hyperuricaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hypocalcaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hypomagnesaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Impaired Fasting Glucose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Iron Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Vitamin D Deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Back Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Fibromyalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Joint Noise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Muscle Spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Musculoskeletal Chest Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Musculoskeletal Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Musculoskeletal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Musculoskeletal Stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Neck Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pain in Extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Spinal Stenosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Trigger Finger', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Leukaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Lipoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Carpal Tunnel Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cerebral Ischaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Disturbance in Attention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 6}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 12}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Memory Impairment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Neuromuscular Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': "Parkinson's Disease", 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Poor Quality Sleep', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Sciatica', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Aggression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Attention Deficit Hyperactivity Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dysphoria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Irritability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Suicidal Ideation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pollakiuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urinary Incontinence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urinary Tract Discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Adenomyosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cervical Polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dysmenorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Menorrhagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Menstruation Irregular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Vaginal Discharge', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dry Throat', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Epistaxis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Nasal Polyps', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Oropharyngeal Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Respiratory Disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Rhinitis Allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Sinus Congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Upper Respiratory Tract Inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Alopecia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Alopecia Areata', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dermatitis Acneiform', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dry Skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Eczema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hyperhidrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ingrowing Nail', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Lichen Planus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Night Sweats', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 5}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 2}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Skin Discolouration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Skin Lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Abortion Induced', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Dental Implantation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 3}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Hypertensive Crisis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}], 'seriousEvents': [{'term': 'Lymphadenitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Cardiac Failure Acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Myocarditis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Colitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Toxic Shock Syndrome Streptococcal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ligament Rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Post-Traumatic Neck Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Intervertebral Disc Protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Muscle Necrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Lung Adenocarcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Ovarian Haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 28, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 66, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 32, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 63, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 33, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 43, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 20, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 48, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA Version 23.0'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels in Currently Not Treated Population at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.251', 'spread': '0.3144', 'groupId': 'OG000'}, {'value': '-0.096', 'spread': '0.3567', 'groupId': 'OG001'}, {'value': '-0.142', 'spread': '0.3443', 'groupId': 'OG002'}, {'value': '-0.203', 'spread': '0.4721', 'groupId': 'OG003'}, {'value': '-0.411', 'spread': '0.4843', 'groupId': 'OG004'}]}]}, {'title': 'HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.015', 'spread': '0.0880', 'groupId': 'OG000'}, {'value': '0.053', 'spread': '0.2066', 'groupId': 'OG001'}, {'value': '0.041', 'spread': '0.0939', 'groupId': 'OG002'}, {'value': '0.064', 'spread': '0.0913', 'groupId': 'OG003'}, {'value': '0.088', 'spread': '0.1613', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 24', 'description': "Change from baseline in HBsAg levels in currently not treated population at Week 24 based on Hepatitis B e Antigen (HBeAg) status was reported. Currently not treated population defined as participants who didn't receive any hepatitis B virus (HBV) treatment 6 months prior to baseline.", 'unitOfMeasure': 'log10 IU per milliliter (log10 IU/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Intent-to-Treat Population (ITT) consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n'(number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'PRIMARY', 'title': 'Change From Baseline in HBsAg Levels in Virologically Suppressed Population at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.008', 'spread': '0.1224', 'groupId': 'OG000'}, {'value': '-0.063', 'spread': '0.2272', 'groupId': 'OG001'}, {'value': '0.105', 'spread': '0.1809', 'groupId': 'OG002'}]}]}, {'title': 'HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.024', 'spread': '0.0722', 'groupId': 'OG000'}, {'value': '-0.017', 'spread': '0.0677', 'groupId': 'OG001'}, {'value': '0.092', 'spread': '0.0556', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Week 24', 'description': 'Change from baseline in HBsAg levels in virologically suppressed population at Week 24 based on HBeAg status was reported. Virologically suppressed population defined as participants who were on entecavir (ETV) or tenofovir disoproxil fumarate (TDF) for at least 12 months prior to screening and had HBV deoxyribonucleic acid (DNA) \\<60 IU/mL. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment- Emergent Adverse Events (AEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '43', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '34', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '25', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 48', 'description': 'An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Treatment-emergent AEs were AEs with onset during the treatment phase or that worsened since baseline.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who received at least one dose of the study agent; all safety endpoints were analyzed by the treatment arm as treated.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '43', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 80', 'description': 'A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who received at least one dose of the study agent; all safety endpoints were analyzed by the treatment arm as treated.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Clinically Significant Changes in Vital Signs, Physical Examinations, Electrocardiogram (ECG), and Clinical Laboratory Tests', 'denoms': [{'units': 'Participants', 'counts': [{'value': '43', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '63', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Vital Signs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Physical Examinations', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'ECG', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Clinical Laboratory Tests: Hematology', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Clinical Laboratory Tests: Blood biochemistry', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Clinical Laboratory Tests: Blood coagulation', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Clinical Laboratory Tests: Urinalysis', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Week 80', 'description': 'Number of participants with clinically significant changes in vital signs, physical examinations, ECG, and clinical laboratory tests (including hematology, blood biochemistry, blood coagulation, and urinalysis) were reported.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who received at least one dose of the study agent; all safety endpoints were analyzed by the treatment arm as treated.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HBsAg Levels in Currently Not Treated Population Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.251', 'spread': '0.3144', 'groupId': 'OG000'}, {'value': '-0.096', 'spread': '0.3567', 'groupId': 'OG001'}, {'value': '-0.142', 'spread': '0.3443', 'groupId': 'OG002'}, {'value': '-0.203', 'spread': '0.4721', 'groupId': 'OG003'}, {'value': '-0.411', 'spread': '0.4843', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.015', 'spread': '0.0880', 'groupId': 'OG000'}, {'value': '0.053', 'spread': '0.2066', 'groupId': 'OG001'}, {'value': '0.041', 'spread': '0.0939', 'groupId': 'OG002'}, {'value': '0.064', 'spread': '0.0913', 'groupId': 'OG003'}, {'value': '0.088', 'spread': '0.1613', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.109', 'spread': '0.2065', 'groupId': 'OG000'}, {'value': '0.061', 'spread': '0.6817', 'groupId': 'OG002'}, {'value': '-0.035', 'spread': '0.6065', 'groupId': 'OG003'}, {'value': '-0.811', 'spread': '1.0053', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.027', 'spread': '0.0969', 'groupId': 'OG000'}, {'value': '-0.024', 'spread': '0.1016', 'groupId': 'OG002'}, {'value': '0.011', 'spread': '0.1086', 'groupId': 'OG003'}, {'value': '0.075', 'spread': '0.1528', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.300', 'spread': '0.3333', 'groupId': 'OG000'}, {'value': '-0.786', 'spread': '0.6879', 'groupId': 'OG001'}, {'value': '-0.404', 'spread': '0.5852', 'groupId': 'OG002'}, {'value': '-0.230', 'spread': '0.5110', 'groupId': 'OG003'}, {'value': '-0.721', 'spread': '0.5666', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0.006', 'spread': '0.1191', 'groupId': 'OG000'}, {'value': '0.000', 'spread': '0.1889', 'groupId': 'OG001'}, {'value': '-0.068', 'spread': '0.0999', 'groupId': 'OG002'}, {'value': '-0.073', 'spread': '0.1195', 'groupId': 'OG003'}, {'value': '-0.017', 'spread': '0.1533', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBsAg levels in currently not treated population based on HBeAg status was reported.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HBsAg Levels in Virologically Suppressed Population Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.008', 'spread': '0.1224', 'groupId': 'OG000'}, {'value': '-0.063', 'spread': '0.2272', 'groupId': 'OG001'}, {'value': '0.105', 'spread': '0.1809', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.024', 'spread': '0.0722', 'groupId': 'OG000'}, {'value': '-0.017', 'spread': '0.0677', 'groupId': 'OG001'}, {'value': '0.092', 'spread': '0.0556', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.043', 'spread': '0.1374', 'groupId': 'OG000'}, {'value': '-0.078', 'spread': '0.2660', 'groupId': 'OG001'}, {'value': '0.046', 'spread': '0.2223', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.011', 'spread': '0.0736', 'groupId': 'OG000'}, {'value': '-0.038', 'spread': '0.0747', 'groupId': 'OG001'}, {'value': '0.029', 'spread': '0.0752', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.088', 'spread': '0.0492', 'groupId': 'OG000'}, {'value': '-0.146', 'spread': '0.2821', 'groupId': 'OG001'}, {'value': '-0.159', 'spread': '0.2141', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.006', 'spread': '0.0789', 'groupId': 'OG000'}, {'value': '-0.119', 'spread': '0.1172', 'groupId': 'OG001'}, {'value': '-0.028', 'spread': '0.0655', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBsAg levels in virologically suppressed population based on HBeAg status was reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Levels Less Than (<) 1,000 or <100 International Units Per Milliliter (IU/mL) in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBsAg<100 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HBsAg<1000 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HBsAg<100 IU/mL: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HBsAg<1000 IU/mL: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '15.4', 'groupId': 'OG000'}, {'value': '23.1', 'groupId': 'OG001'}, {'value': '4.8', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '10.5', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBsAg<100 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBsAg<1000 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '50.0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '20.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBsAg<100 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBsAg<1000 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '18.2', 'groupId': 'OG000'}, {'value': '22.2', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '14.3', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24:HBsAg<100 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24:HBsAg<1000 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '10.0', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '9.1', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24:HBsAg<100 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBsAg<1000 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '18.2', 'groupId': 'OG000'}, {'value': '23.1', 'groupId': 'OG001'}, {'value': '18.8', 'groupId': 'OG002'}, {'value': '7.1', 'groupId': 'OG003'}, {'value': '5.9', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with HBsAg levels \\<1,000 or \\<100 IU/mL in currently not treated population based on their HBeAg status were reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Levels <1,000 or <100 IU/mL in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBsAg<100 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HBsAg<1000 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '11.1', 'groupId': 'OG001'}, {'value': '10.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HBsAg<100 IU/mL: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HBsAg<1000 IU/mL: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '29.2', 'groupId': 'OG001'}, {'value': '15.8', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBsAg<100 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBsAg<1000 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '12.5', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBsAg<100 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBsAg<1000 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '7.7', 'groupId': 'OG000'}, {'value': '33.3', 'groupId': 'OG001'}, {'value': '20.0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBsAg<100 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '11.1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBsAg<1000 IU/mL: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000'}, {'value': '11.1', 'groupId': 'OG001'}, {'value': '44.4', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBsAg<100 IU/mL: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBsAg<1000 IU/mL: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '13.3', 'groupId': 'OG000'}, {'value': '34.8', 'groupId': 'OG001'}, {'value': '7.1', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with HBsAg levels \\<1,000 or \\<100 IU/mL in virologically suppressed population based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Greater Than (>) 0.5 log10 IU/mL or >1 log10 IU/mL Reduction in HBsAg From Baseline in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: >0.5 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '12.5', 'groupId': 'OG000'}, {'value': '12.5', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '28.6', 'groupId': 'OG003'}, {'value': '36.4', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: >1 log10IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '7.1', 'groupId': 'OG003'}, {'value': '18.2', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: >0.5 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: >1 log10 IU/mL: Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: >0.5 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '60.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: >1 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '60.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: >0.5 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: >1 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: >0.5 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '60.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}, {'value': '30.0', 'groupId': 'OG003'}, {'value': '54.5', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: >1 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '40.0', 'groupId': 'OG001'}, {'value': '16.7', 'groupId': 'OG002'}, {'value': '7.7', 'groupId': 'OG003'}, {'value': '27.3', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: >0.5 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: >1 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL or \\>1 log10 IU/mL reduction in HBsAg from baseline in currently not treated population based on their HBeAg status were reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With >0.5 log10 IU/mL or >1 log10 IU/mL Reduction in HBsAg From Baseline in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: >0.5 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: >1 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: >0.5 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: >1 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: >0.5 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '12.5', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: >1 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: >0.5 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: >1 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: >0.5 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '11.1', 'groupId': 'OG001'}, {'value': '11.1', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: >1 log10 IU/mL: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: >0.5 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: >1 log10 IU/mL: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL or \\>1 log10 IU/mL reduction in HBsAg from baseline in virologically suppressed population based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-5.211', 'spread': '1.1986', 'groupId': 'OG000'}, {'value': '-3.284', 'spread': '2.1148', 'groupId': 'OG001'}, {'value': '-5.531', 'spread': '0.7915', 'groupId': 'OG002'}, {'value': '-5.719', 'spread': '0.8395', 'groupId': 'OG003'}, {'value': '-5.883', 'spread': '1.1396', 'groupId': 'OG004'}]}]}, {'title': 'Week 24:HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.622', 'spread': '1.3003', 'groupId': 'OG000'}, {'value': '-3.469', 'spread': '1.2901', 'groupId': 'OG001'}, {'value': '-4.077', 'spread': '0.9435', 'groupId': 'OG002'}, {'value': '-3.545', 'spread': '1.1482', 'groupId': 'OG003'}, {'value': '-3.690', 'spread': '1.5289', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-6.359', 'spread': '0.1989', 'groupId': 'OG000'}, {'value': '-5.009', 'spread': '1.8289', 'groupId': 'OG002'}, {'value': '-6.413', 'spread': '0.9121', 'groupId': 'OG003'}, {'value': '-6.205', 'spread': '1.3358', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.650', 'spread': '1.3342', 'groupId': 'OG000'}, {'value': '-3.707', 'spread': '1.6444', 'groupId': 'OG002'}, {'value': '-3.313', 'spread': '1.0138', 'groupId': 'OG003'}, {'value': '-3.520', 'spread': '1.2505', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-5.956', 'spread': '0.6580', 'groupId': 'OG000'}, {'value': '-6.318', 'spread': '1.0238', 'groupId': 'OG001'}, {'value': '-6.080', 'spread': '0.8678', 'groupId': 'OG002'}, {'value': '-6.262', 'spread': '0.6278', 'groupId': 'OG003'}, {'value': '-6.013', 'spread': '1.8359', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-3.727', 'spread': '1.6598', 'groupId': 'OG000'}, {'value': '-4.805', 'spread': '1.0557', 'groupId': 'OG001'}, {'value': '-4.165', 'spread': '1.1102', 'groupId': 'OG002'}, {'value': '-3.721', 'spread': '1.1937', 'groupId': 'OG003'}, {'value': '-3.906', 'spread': '1.6486', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBV DNA levels in currently not treated population based on their HBeAg status was reported.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who are randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants would be shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HBV DNA Levels in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.051', 'spread': '0.1142', 'groupId': 'OG000'}, {'value': '0.000', 'spread': '0.3374', 'groupId': 'OG001'}, {'value': '0.021', 'spread': '0.2665', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.032', 'spread': '0.2184', 'groupId': 'OG000'}, {'value': '0.016', 'spread': '0.3626', 'groupId': 'OG001'}, {'value': '-0.024', 'spread': '0.2472', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.044', 'spread': '0.2660', 'groupId': 'OG000'}, {'value': '0.000', 'spread': '0.3607', 'groupId': 'OG001'}, {'value': '-0.233', 'spread': '0.2817', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.000', 'spread': '0.3896', 'groupId': 'OG000'}, {'value': '-0.010', 'spread': '0.3403', 'groupId': 'OG001'}, {'value': '-0.093', 'spread': '0.2645', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.175', 'spread': '0.3644', 'groupId': 'OG000'}, {'value': '0.000', 'spread': '0.3374', 'groupId': 'OG001'}, {'value': '0.105', 'spread': '0.5370', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.032', 'spread': '0.2832', 'groupId': 'OG000'}, {'value': '-0.069', 'spread': '0.3767', 'groupId': 'OG001'}, {'value': '0.070', 'spread': '0.3124', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBV DNA levels in virologically supressed population based on their HBeAg status was reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who are randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants would be shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Undetectable HBV DNA Levels in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '30', 'groupId': 'OG003'}, {'value': '30', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '9.1', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}, {'value': '19', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '23.1', 'groupId': 'OG000'}, {'value': '14.3', 'groupId': 'OG001'}, {'value': '14.3', 'groupId': 'OG002'}, {'value': '18.8', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '27.3', 'groupId': 'OG000'}, {'value': '55.6', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '28.6', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '15.4', 'groupId': 'OG003'}, {'value': '11.9', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '36.4', 'groupId': 'OG000'}, {'value': '38.5', 'groupId': 'OG001'}, {'value': '18.8', 'groupId': 'OG002'}, {'value': '35.7', 'groupId': 'OG003'}, {'value': '23.5', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with undetectable HBV DNA levels in currently not treated population based on their HBeAg status was evaluated.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Undetectable HBV DNA Levels in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml)) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '40.0', 'groupId': 'OG000'}, {'value': '22.2', 'groupId': 'OG001'}, {'value': '40.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '60.0', 'groupId': 'OG000'}, {'value': '58.3', 'groupId': 'OG001'}, {'value': '63.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '40.0', 'groupId': 'OG000'}, {'value': '37.5', 'groupId': 'OG001'}, {'value': '77.8', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '53.8', 'groupId': 'OG000'}, {'value': '66.7', 'groupId': 'OG001'}, {'value': '66.7', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000'}, {'value': '44.4', 'groupId': 'OG001'}, {'value': '44.4', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '60.0', 'groupId': 'OG000'}, {'value': '73.9', 'groupId': 'OG001'}, {'value': '42.9', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with undetectable HBV DNA levels in virologically suppressed population based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HBeAg Levels in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-0.811', 'spread': '0.7953', 'groupId': 'OG000'}, {'value': '-0.456', 'spread': '0.2908', 'groupId': 'OG001'}, {'value': '-0.487', 'spread': '2974', 'groupId': 'OG002'}, {'value': '-0.974', 'spread': '0.8400', 'groupId': 'OG003'}, {'value': '-0.701', 'spread': '0.6645', 'groupId': 'OG004'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-2.250', 'spread': '0.4010', 'groupId': 'OG000'}, {'value': '-0.235', 'spread': '0.0908', 'groupId': 'OG002'}, {'value': '-1.779', 'spread': '1.3525', 'groupId': 'OG003'}, {'value': '-1.601', 'spread': '1.2689', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-1.139', 'spread': '1.2528', 'groupId': 'OG000'}, {'value': '-1.597', 'spread': '1.1587', 'groupId': 'OG001'}, {'value': '-0.876', 'spread': '0.5178', 'groupId': 'OG002'}, {'value': '-1.243', 'spread': '0.9933', 'groupId': 'OG003'}, {'value': '-1.215', 'spread': '1.2910', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBeAg levels in HBeAg positive currently not treated population was reported.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HBeAg Levels in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.313', 'spread': '0.5281', 'groupId': 'OG000'}, {'value': '-0.315', 'spread': '0.4681', 'groupId': 'OG001'}, {'value': '-0.162', 'spread': '0.2037', 'groupId': 'OG002'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.589', 'spread': '0.6616', 'groupId': 'OG000'}, {'value': '-0.393', 'spread': '0.4866', 'groupId': 'OG001'}, {'value': '-0.291', 'spread': '0.2376', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '-0.772', 'spread': '0.7059', 'groupId': 'OG000'}, {'value': '-0.387', 'spread': '0.5218', 'groupId': 'OG001'}, {'value': '-0.351', 'spread': '0.2877', 'groupId': 'OG002'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBeAg levels in HBeAg positive virologically suppressed population was reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'log10 IU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With >0.5 log10 IU/mL and >1 log10 IU/mL Reduction in HBeAg From Baseline in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: >0.5 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '62.5', 'groupId': 'OG000'}, {'value': '50', 'groupId': 'OG001'}, {'value': '41.7', 'groupId': 'OG002'}, {'value': '78.6', 'groupId': 'OG003'}, {'value': '63.6', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: >1 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '37.5', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '8.3', 'groupId': 'OG002'}, {'value': '42.9', 'groupId': 'OG003'}, {'value': '36.4', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: >0.5 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '100', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '100.0', 'groupId': 'OG003'}, {'value': '80.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: >1 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '80.0', 'groupId': 'OG003'}, {'value': '80.0', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: >0.5 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}, {'value': '80.0', 'groupId': 'OG001'}, {'value': '91.7', 'groupId': 'OG002'}, {'value': '84.6', 'groupId': 'OG003'}, {'value': '72.7', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: >1 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}, {'value': '70.0', 'groupId': 'OG001'}, {'value': '25.0', 'groupId': 'OG002'}, {'value': '61.5', 'groupId': 'OG003'}, {'value': '45.5', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL and \\>1 log10 IU/mL reduction in HBeAg from baseline in HBeAg positive currently not treated population was reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With >0.5 log10 IU/mL and >1 log10 IU/mL Reduction in HBeAg From Baseline in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: >0.5 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '33.3', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: >1 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '11.1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: >0.5 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '22.2', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: >1 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '25.0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: >0.5 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '22.2', 'groupId': 'OG001'}, {'value': '22.2', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: >1 log10 IU/mL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000'}, {'value': '11.1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL and \\>1 log10 IU/mL reduction in HBeAg from baseline in HBeAg positive virologically suppressed population was reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Seroclearance in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '29', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '15', 'groupId': 'OG003'}, {'value': '18', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroclearance in currently not treated population based on their HBeAg status were reported. Seroclearance at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at Week 24/48. Loss is defined as a baseline HBsAg with a repeat reactive, confirmed or positive result and a post-baseline assessment with a negative result. This outcome measure was planned to be analyzed at specified timepoints only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here, 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Seroclearance in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroclearance in virologically suppressed population based on their HBeAg status were reported. Seroclearance at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at Week 24/48. Loss is defined as a baseline HBsAg with a repeat reactive, confirmed or positive result and a post-baseline assessment with a negative result. This outcome measure was planned to be analyzed for specified arms and specific timepoints only .', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here, 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Seroconversion in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '28', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase.Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HbeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '15', 'groupId': 'OG003'}, {'value': '18', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '14', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroconversion in currently not treated population based on their HBeAg status were reported. Seroconversion at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at week 24/48 of the treatment and an appearance of Anti-HBs. This outcome measure was planned to be analyzed for specified timepoints only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With HBsAg Seroconversion in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '29', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HbeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '19', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}, {'value': '0.0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroconversion in virologically suppressed population based on their HBeAg status were reported. Seroconversion at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at week 24/48 of the treatment and an appearance of Anti-HBs. This outcome measure was planned to be analyzed for specified arms and specified timepoints only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Normalized Alanine Aminotransferase (ALT) Levels in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '27', 'groupId': 'OG002'}, {'value': '25', 'groupId': 'OG003'}, {'value': '24', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '62.5', 'groupId': 'OG000'}, {'value': '60.0', 'groupId': 'OG001'}, {'value': '54.5', 'groupId': 'OG002'}, {'value': '64.3', 'groupId': 'OG003'}, {'value': '44.4', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '16', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '15', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '55.6', 'groupId': 'OG000'}, {'value': '91.7', 'groupId': 'OG001'}, {'value': '68.8', 'groupId': 'OG002'}, {'value': '72.7', 'groupId': 'OG003'}, {'value': '80.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '40.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '11', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '75.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG002'}, {'value': '77.8', 'groupId': 'OG003'}, {'value': '63.6', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '71.4', 'groupId': 'OG000'}, {'value': '71.4', 'groupId': 'OG001'}, {'value': '63.6', 'groupId': 'OG002'}, {'value': '61.5', 'groupId': 'OG003'}, {'value': '77.8', 'groupId': 'OG004'}]}]}, {'title': 'Follow-up Week 24: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '15', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '87.5', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '83.3', 'groupId': 'OG002'}, {'value': '90.9', 'groupId': 'OG003'}, {'value': '86.7', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with normalized ALT levels in currently not treated population, whose ALT levels were above upper limit of normal at baseline based on their HBeAg status were reported.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "The safety population included all participants who received at least one dose of the study agent with ALT values higher than upper limit of normal (ULN) at baseline if time point is available; all safety endpoints were analyzed by the treatment arm as treated. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Normalized ALT Levels in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HBeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBeAg positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '50.0', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG001'}, {'value': '33.3', 'groupId': 'OG002'}]}]}, {'title': 'Follow-up Week 24: HBeAg negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}, {'value': '66.7', 'groupId': 'OG001'}, {'value': '100.0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with normalized ALT levels in virologically suppressed population, whose ALT levels were above upper limit of normal at baseline based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "The safety population included all participants who received at least one dose of the study agent with ALT values higher than ULN at baseline if time point is available; all safety endpoints were analyzed by the treatment arm as treated. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Virological Breakthrough in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}, {'value': '33', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '13', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '16.7', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}, {'value': '20', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '18.8', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '5.6', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG002'}, {'value': '100.0', 'groupId': 'OG003'}, {'value': '100.0', 'groupId': 'OG004'}]}]}, {'title': 'Week 48: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '16', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '33.3', 'groupId': 'OG001'}, {'value': '10.0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with virological breakthrough in currently not treated population based on their HBeAg status was reported. Virological breakthrough defined as confirmed on treatment HBV DNA increase by \\>1 log10 from nadir level or confirmed on treatment level \\>200 IU/mL in participants who had HBV DNA level below the lower limit of quantification (LLOQ) of the HBV DNA assay.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here, 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Virological Breakthrough in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Week 24: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 24: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '20', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Positive', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Week 48: HbeAg Negative', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '17', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with virological breakthrough in virologically suppressed population based on their HBeAg status was reported. Virological breakthrough defined as confirmed on treatment HBV DNA increase by \\>1 log10 from nadir level or confirmed on treatment level \\>200 IU/mL in participants who had HBV DNA level below the lower limit of quantification (LLOQ) of the HBV DNA assay. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of Entecavir [ETV] in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Placebo (Matching JNJ-56136379 75 mg) + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\]) plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part B: Placebo (Matching to JNJ-56136379 250 mg) + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (250 mg) plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks."}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}], 'classes': [{'title': 'Day 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG003'}]}]}, {'title': 'Day 1: 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '1.39', 'spread': '0.709', 'groupId': 'OG002'}, {'value': '1.18', 'spread': '0.197', 'groupId': 'OG003'}]}]}, {'title': 'Week 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.321', 'spread': '0.0961', 'groupId': 'OG002'}, {'value': '0.289', 'spread': '0.0351', 'groupId': 'OG003'}]}]}, {'title': 'Week 2: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.285', 'spread': '0.166', 'groupId': 'OG002'}, {'value': '0.377', 'spread': '0.0531', 'groupId': 'OG003'}]}]}, {'title': 'Week 4: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.417', 'spread': '0.143', 'groupId': 'OG002'}, {'value': '0.414', 'spread': '0.0742', 'groupId': 'OG003'}]}]}, {'title': 'Week 8: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.353', 'spread': '0.226', 'groupId': 'OG002'}, {'value': '0.466', 'spread': '0.0913', 'groupId': 'OG003'}]}]}, {'title': 'Week 12: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.467', 'spread': '0.188', 'groupId': 'OG002'}, {'value': '0.479', 'spread': '0.0650', 'groupId': 'OG003'}]}]}, {'title': 'Week 20: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.441', 'spread': '0.147', 'groupId': 'OG002'}, {'value': '0.481', 'spread': '0.0625', 'groupId': 'OG003'}]}]}, {'title': 'Week 24: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.395', 'spread': '0.309', 'groupId': 'OG002'}, {'value': '0.385', 'spread': '0.0415', 'groupId': 'OG003'}]}]}, {'title': 'Week 28: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG002'}, {'value': '0.527', 'spread': '0.0302', 'groupId': 'OG003'}]}]}, {'title': 'Week 32: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG002'}, {'value': '0.462', 'spread': '0.0410', 'groupId': 'OG003'}]}]}, {'title': 'Week 36: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG002'}, {'value': '0.442', 'spread': '0.0517', 'groupId': 'OG003'}]}]}, {'title': 'Week 44: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG002'}, {'value': '0.438', 'spread': '0.0352', 'groupId': 'OG003'}]}]}, {'title': 'Week 48: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': '0.434', 'spread': '0.0968', 'groupId': 'OG002'}, {'value': '0.539', 'spread': '0.0414', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.542', 'spread': '0.311', 'groupId': 'OG002'}, {'value': '0.307', 'spread': '0.176', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.354', 'spread': '0.260', 'groupId': 'OG002'}, {'value': '0.309', 'spread': '0.161', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of ETV administered as monotherapy or co-administered with JNJ-56136379 in currently not treated population was determined. As planned, plasma concentration of ETV co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.', 'unitOfMeasure': 'nanograms per milliliter (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "The pharmacokinetic (PK) analysis set included data for all participants with available plasma concentrations. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified timepoints."}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of ETV in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Placebo (Matching JNJ-56136379 75 mg) + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\]) plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part B: Placebo (Matching to JNJ-56136379 250 mg) + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on entecavir \\[ETV\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (250 mg) plus 1 tablet of NA (05 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}], 'classes': [{'title': 'Day 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG000'}, {'value': '0.683', 'spread': '0.414', 'groupId': 'OG002'}]}]}, {'title': 'Day 1: 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': '1.86', 'spread': '0.639', 'groupId': 'OG002'}, {'value': '1.89', 'spread': '0.429', 'groupId': 'OG003'}]}]}, {'title': 'Week 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1.94', 'spread': '2.43', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.464', 'spread': '0.143', 'groupId': 'OG002'}, {'value': '0.472', 'spread': '0.120', 'groupId': 'OG003'}]}]}, {'title': 'Week 2: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.871', 'spread': '0.909', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.469', 'spread': '0.153', 'groupId': 'OG002'}, {'value': '0.469', 'spread': '0.0835', 'groupId': 'OG003'}]}]}, {'title': 'Week 4: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.647', 'spread': '0.628', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.529', 'spread': '0.198', 'groupId': 'OG002'}, {'value': '0.539', 'spread': '0.108', 'groupId': 'OG003'}]}]}, {'title': 'Week 8: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.496', 'spread': '0.179', 'groupId': 'OG002'}, {'value': '0.493', 'spread': '0.0816', 'groupId': 'OG003'}]}]}, {'title': 'Week 12: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.277', 'spread': '0.0733', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.454', 'spread': '0.135', 'groupId': 'OG002'}, {'value': '0.548', 'spread': '0.0535', 'groupId': 'OG003'}]}]}, {'title': 'Week 20: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.617', 'spread': '0.408', 'groupId': 'OG002'}, {'value': '0.537', 'spread': '0.109', 'groupId': 'OG003'}]}]}, {'title': 'Week 24: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': '0.491', 'spread': '0.144', 'groupId': 'OG002'}, {'value': '0.576', 'spread': '0.121', 'groupId': 'OG003'}]}]}, {'title': 'Week 28: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': '0.446', 'spread': '0.148', 'groupId': 'OG002'}, {'value': '0.519', 'spread': '0.153', 'groupId': 'OG003'}]}]}, {'title': 'Week 32: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': '0.467', 'spread': '0.201', 'groupId': 'OG002'}, {'value': '0.489', 'spread': '0.144', 'groupId': 'OG003'}]}]}, {'title': 'Week 36: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.962', 'spread': '1.07', 'groupId': 'OG000'}, {'value': '0.487', 'spread': '0.185', 'groupId': 'OG002'}, {'value': '0.526', 'spread': '0.109', 'groupId': 'OG003'}]}]}, {'title': 'Week 44: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': '0.525', 'spread': '0.177', 'groupId': 'OG002'}, {'value': '0.517', 'spread': '0.121', 'groupId': 'OG003'}]}]}, {'title': 'Week 48: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.766', 'spread': '0.594', 'groupId': 'OG000'}, {'value': '0.554', 'spread': '0.287', 'groupId': 'OG002'}, {'value': '0.537', 'spread': '0.105', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.635', 'spread': '0.449', 'groupId': 'OG002'}, {'value': '0.433', 'spread': '0.117', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '10', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1.00', 'spread': '1.13', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '0.445', 'spread': '0.164', 'groupId': 'OG002'}, {'value': '0.725', 'spread': '0.598', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of ETV administered as monotherapy or co-administered with JNJ-56136379 in virologically suppressed population was determined. As planned, plasma concentration of ETV co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "The PK analysis set included data for all participants with available plasma concentrations. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified timepoints."}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of Tenofovir Disoproxil Fumarate (TDF) in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}, {'value': '25', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Placebo (Matching JNJ-56136379 75 mg) + Nucleos(t)Ide Analog (NA)', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\]) plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks."}, {'id': 'OG001', 'title': 'Part B: Placebo (Matching to JNJ-56136379 250 mg) + NA', 'description': "Currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received matching placebo to JNJ-56136379 (250 mg) plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks."}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.)'}], 'classes': [{'title': 'Day 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not estimable due to small sample size.', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG003'}]}]}, {'title': 'Day 1: 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '25', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '277', 'spread': '116', 'groupId': 'OG000'}, {'value': '170', 'spread': '114', 'groupId': 'OG001'}, {'value': '372', 'spread': '478', 'groupId': 'OG002'}, {'value': '249', 'spread': '96.9', 'groupId': 'OG003'}]}]}, {'title': 'Week 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '79.6', 'spread': '38.1', 'groupId': 'OG000'}, {'value': '92.7', 'spread': '134', 'groupId': 'OG001'}, {'value': '92.6', 'spread': '37.4', 'groupId': 'OG002'}, {'value': '97.8', 'spread': '27.7', 'groupId': 'OG003'}]}]}, {'title': 'Week 2: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '64.2', 'spread': '34.5', 'groupId': 'OG000'}, {'value': '50.1', 'spread': '14.1', 'groupId': 'OG001'}, {'value': '81.5', 'spread': '22.6', 'groupId': 'OG002'}, {'value': '97.6', 'spread': '23.7', 'groupId': 'OG003'}]}]}, {'title': 'Week 4: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '62.9', 'spread': '17.7', 'groupId': 'OG000'}, {'value': '46.5', 'spread': '10.5', 'groupId': 'OG001'}, {'value': '90.2', 'spread': '25.8', 'groupId': 'OG002'}, {'value': '99.6', 'spread': '26.4', 'groupId': 'OG003'}]}]}, {'title': 'Week 8: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}, {'value': '23', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '66.3', 'spread': '23.7', 'groupId': 'OG000'}, {'value': '54.2', 'spread': '18.3', 'groupId': 'OG001'}, {'value': '92.6', 'spread': '25.7', 'groupId': 'OG002'}, {'value': '108', 'spread': '36.0', 'groupId': 'OG003'}]}]}, {'title': 'Week 12: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}, {'value': '23', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '67.5', 'spread': '31.2', 'groupId': 'OG000'}, {'value': '51.3', 'spread': '15.9', 'groupId': 'OG001'}, {'value': '92.6', 'spread': '29.1', 'groupId': 'OG002'}, {'value': '102', 'spread': '35.3', 'groupId': 'OG003'}]}]}, {'title': 'Week 20: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}, {'value': '23', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '72.6', 'spread': '34.2', 'groupId': 'OG000'}, {'value': '51.2', 'spread': '13.8', 'groupId': 'OG001'}, {'value': '85.8', 'spread': '30.6', 'groupId': 'OG002'}, {'value': '115', 'spread': '41.7', 'groupId': 'OG003'}]}]}, {'title': 'Week 24: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}, {'value': '23', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '75.9', 'spread': '51.0', 'groupId': 'OG000'}, {'value': '50.5', 'spread': '20.1', 'groupId': 'OG001'}, {'value': '89.1', 'spread': '30.1', 'groupId': 'OG002'}, {'value': '99.3', 'spread': '37.8', 'groupId': 'OG003'}]}]}, {'title': 'Week 28: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '17', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '74.4', 'spread': '38.1', 'groupId': 'OG000'}, {'value': '51.2', 'spread': '19.9', 'groupId': 'OG001'}, {'value': '99.0', 'spread': '32.6', 'groupId': 'OG002'}, {'value': '108', 'spread': '39.0', 'groupId': 'OG003'}]}]}, {'title': 'Week 32: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '78.8', 'spread': '59.6', 'groupId': 'OG000'}, {'value': '52.7', 'spread': '26.1', 'groupId': 'OG001'}, {'value': '89.6', 'spread': '37.1', 'groupId': 'OG002'}, {'value': '88.5', 'spread': '25.6', 'groupId': 'OG003'}]}]}, {'title': 'Week 36: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '78.9', 'spread': '55.8', 'groupId': 'OG000'}, {'value': '42.5', 'spread': '19.3', 'groupId': 'OG001'}, {'value': '96.0', 'spread': '38.3', 'groupId': 'OG002'}, {'value': '101', 'spread': '34.2', 'groupId': 'OG003'}]}]}, {'title': 'Week 44: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '86.3', 'spread': '30.8', 'groupId': 'OG000'}, {'value': '46.3', 'spread': '26.0', 'groupId': 'OG001'}, {'value': '81.8', 'spread': '38.9', 'groupId': 'OG002'}, {'value': '105', 'spread': '33.5', 'groupId': 'OG003'}]}]}, {'title': 'Week 48: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '15', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '76.4', 'spread': '40', 'groupId': 'OG000'}, {'value': '47.8', 'spread': '18.6', 'groupId': 'OG001'}, {'value': '89.5', 'spread': '49.8', 'groupId': 'OG002'}, {'value': '100', 'spread': '29.9', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '73.8', 'spread': '37.1', 'groupId': 'OG000'}, {'value': '52.1', 'spread': '17.3', 'groupId': 'OG001'}, {'value': '65.7', 'spread': '29.5', 'groupId': 'OG002'}, {'value': '73.5', 'spread': '23.2', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '22', 'groupId': 'OG002'}, {'value': '21', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '72.4', 'spread': '32.1', 'groupId': 'OG000'}, {'value': '57.1', 'spread': '13.6', 'groupId': 'OG001'}, {'value': '68.7', 'spread': '54.3', 'groupId': 'OG002'}, {'value': '68.4', 'spread': '43.6', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of TDF administered as monotherapy or co-administered with JNJ-56136379 was determined. As planned, plasma concentration of TDF co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.', 'unitOfMeasure': 'nanograms per milliliter (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "The PK analysis set included data for all participants with available plasma concentrations. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified timepoints."}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of TDF in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: Placebo (Matching JNJ-56136379 75 mg) + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (75 milligrams \\[mg\\]) plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part B: Placebo (Matching JNJ-56136379 250 mg) + Nucleos(t)Ide Analog (NA)', 'description': 'Virologically suppressed (who were on tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] \\<60 IU/ml) participants received matching placebo to JNJ-56136379 (250 mg) plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Day 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': '68.9', 'spread': '10.1', 'groupId': 'OG002'}, {'value': '63.3', 'spread': '27.4', 'groupId': 'OG003'}]}]}, {'title': 'Day 1: 2 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '274', 'spread': '153', 'groupId': 'OG000'}, {'value': '311', 'spread': '92.5', 'groupId': 'OG001'}, {'value': '306', 'spread': '145', 'groupId': 'OG002'}, {'value': '364', 'spread': '260', 'groupId': 'OG003'}]}]}, {'title': 'Week 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '76.8', 'spread': '40.8', 'groupId': 'OG000'}, {'value': '59.2', 'spread': '15.7', 'groupId': 'OG001'}, {'value': '97.9', 'spread': '38.0', 'groupId': 'OG002'}, {'value': '97.1', 'spread': '36.8', 'groupId': 'OG003'}]}]}, {'title': 'Week 2: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '82.0', 'spread': '53.0', 'groupId': 'OG000'}, {'value': '65.9', 'spread': '18.9', 'groupId': 'OG001'}, {'value': '97.5', 'spread': '34.0', 'groupId': 'OG002'}, {'value': '114', 'spread': '51.0', 'groupId': 'OG003'}]}]}, {'title': 'Week 4: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '83.1', 'spread': '54.8', 'groupId': 'OG000'}, {'value': '66.9', 'spread': '20.3', 'groupId': 'OG001'}, {'value': '96.9', 'spread': '25.0', 'groupId': 'OG002'}, {'value': '110', 'spread': '41.4', 'groupId': 'OG003'}]}]}, {'title': 'Week 8: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '84.0', 'spread': '54.1', 'groupId': 'OG000'}, {'value': '65.5', 'spread': '28.9', 'groupId': 'OG001'}, {'value': '118', 'spread': '48.0', 'groupId': 'OG002'}, {'value': '109', 'spread': '32.2', 'groupId': 'OG003'}]}]}, {'title': 'Week 12: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '98.8', 'spread': '73.6', 'groupId': 'OG000'}, {'value': '63.5', 'spread': '21.6', 'groupId': 'OG001'}, {'value': '99.4', 'spread': '33.8', 'groupId': 'OG002'}, {'value': '130', 'spread': '87.8', 'groupId': 'OG003'}]}]}, {'title': 'Week 20: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '99.6', 'spread': '85.0', 'groupId': 'OG000'}, {'value': '64.8', 'spread': '23.3', 'groupId': 'OG001'}, {'value': '120', 'spread': '30.1', 'groupId': 'OG002'}, {'value': '127', 'spread': '64.9', 'groupId': 'OG003'}]}]}, {'title': 'Week 24: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '78.3', 'spread': '33.4', 'groupId': 'OG000'}, {'value': '73.8', 'spread': '33.0', 'groupId': 'OG001'}, {'value': '104', 'spread': '29.9', 'groupId': 'OG002'}, {'value': '113', 'spread': '47.6', 'groupId': 'OG003'}]}]}, {'title': 'Week 28: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '81.7', 'spread': '37.7', 'groupId': 'OG000'}, {'value': '70.6', 'spread': '28.1', 'groupId': 'OG001'}, {'value': '110', 'spread': '43.2', 'groupId': 'OG002'}, {'value': '155', 'spread': '107', 'groupId': 'OG003'}]}]}, {'title': 'Week 32: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '75.5', 'spread': '54.8', 'groupId': 'OG000'}, {'value': '61.2', 'spread': '21.2', 'groupId': 'OG001'}, {'value': '43.2', 'spread': '36.4', 'groupId': 'OG002'}, {'value': '139', 'spread': '93.3', 'groupId': 'OG003'}]}]}, {'title': 'Week 36: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '80.2', 'spread': '50.3', 'groupId': 'OG000'}, {'value': '80.2', 'spread': '31.2', 'groupId': 'OG001'}, {'value': '101', 'spread': '33.1', 'groupId': 'OG002'}, {'value': '132', 'spread': '90.2', 'groupId': 'OG003'}]}]}, {'title': 'Week 44: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '72.7', 'spread': '54.9', 'groupId': 'OG000'}, {'value': '93.0', 'spread': '64.2', 'groupId': 'OG001'}, {'value': '109', 'spread': '53.4', 'groupId': 'OG002'}, {'value': '129', 'spread': '73.6', 'groupId': 'OG003'}]}]}, {'title': 'Week 48: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '87.6', 'spread': '58.5', 'groupId': 'OG000'}, {'value': '66.2', 'spread': '22.1', 'groupId': 'OG001'}, {'value': '114', 'spread': '31.7', 'groupId': 'OG002'}, {'value': '133', 'spread': '117', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '10', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '86.5', 'spread': '73.8', 'groupId': 'OG000'}, {'value': '51.9', 'spread': '23.4', 'groupId': 'OG001'}, {'value': '73.2', 'spread': '18.5', 'groupId': 'OG002'}, {'value': '136', 'spread': '95.5', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '74.7', 'spread': '47.6', 'groupId': 'OG000'}, {'value': '59.7', 'spread': '23.4', 'groupId': 'OG001'}, {'value': '71.2', 'spread': '33.0', 'groupId': 'OG002'}, {'value': '95.8', 'spread': '83.6', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of TDF administered as monotherapy or co-administered with JNJ-56136379 was determined. As planned, plasma concentration of TDF co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "The PK analysis set included data for all participants with available plasma concentrations. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified timepoints."}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of JNJ-56136379 in Currently Not Treated Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '25', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and receive treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part A: JNJ-56136379 75 mg + NA (ETV)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part A: JNJ-56136379 75 mg + NA (TDF)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}, {'id': 'OG004', 'title': 'Part B: JNJ-56136379 250 mg + NA (ETV)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG005', 'title': 'Part B: JNJ-56136379 250 mg + NA (TDF)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Day 1: 0 hour', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due to below qualification limit (BQL) that is \\<10.0 ng/mL.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due to below qualification limit (BQL) that is \\<10.0 ng/mL.', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG002'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due to below qualification limit (BQL) that is \\<10.0 ng/mL.', 'groupId': 'OG003'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due below qualification limit BQL limit \\<10.0 ng/mL.', 'groupId': 'OG004'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due below qualification limit BQL limit \\<10.0 ng/mL.', 'groupId': 'OG005'}]}]}, {'title': 'Day 1: 2 hour', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '22', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '25', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '709', 'spread': '307', 'groupId': 'OG000'}, {'value': '2143', 'spread': '1300', 'groupId': 'OG001'}, {'value': '520', 'spread': '279', 'groupId': 'OG002'}, {'value': '806', 'spread': '306', 'groupId': 'OG003'}, {'value': '2287', 'spread': '946', 'groupId': 'OG004'}, {'value': '2021', 'spread': '893', 'groupId': 'OG005'}]}]}, {'title': 'Week 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2269', 'spread': '597', 'groupId': 'OG000'}, {'value': '7339', 'spread': '2040', 'groupId': 'OG001'}, {'value': '2264', 'spread': '455', 'groupId': 'OG002'}, {'value': '2368', 'spread': '695', 'groupId': 'OG003'}, {'value': '6461', 'spread': '2014', 'groupId': 'OG004'}, {'value': '7138', 'spread': '2280', 'groupId': 'OG005'}]}]}, {'title': 'Week 2: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '23', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3424', 'spread': '845', 'groupId': 'OG000'}, {'value': '10894', 'spread': '2631', 'groupId': 'OG001'}, {'value': '3094', 'spread': '892', 'groupId': 'OG002'}, {'value': '3702', 'spread': '1028', 'groupId': 'OG003'}, {'value': '9381', 'spread': '2168', 'groupId': 'OG004'}, {'value': '10588', 'spread': '3568', 'groupId': 'OG005'}]}]}, {'title': 'Week 4: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '23', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '24', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '4116', 'spread': '941', 'groupId': 'OG000'}, {'value': '12827', 'spread': '3104', 'groupId': 'OG001'}, {'value': '4368', 'spread': '1216', 'groupId': 'OG002'}, {'value': '4697', 'spread': '1474', 'groupId': 'OG003'}, {'value': '10760', 'spread': '2162', 'groupId': 'OG004'}, {'value': '12513', 'spread': '4229', 'groupId': 'OG005'}]}]}, {'title': 'Week 8: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '22', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '4617', 'spread': '1195', 'groupId': 'OG000'}, {'value': '13697', 'spread': '3702', 'groupId': 'OG001'}, {'value': '5006', 'spread': '1528', 'groupId': 'OG002'}, {'value': '4719', 'spread': '1465', 'groupId': 'OG003'}, {'value': '11027', 'spread': '2009', 'groupId': 'OG004'}, {'value': '13037', 'spread': '4394', 'groupId': 'OG005'}]}]}, {'title': 'Week 12: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '23', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '4130', 'spread': '1145', 'groupId': 'OG000'}, {'value': '12676', 'spread': '3431', 'groupId': 'OG001'}, {'value': '4976', 'spread': '1302', 'groupId': 'OG002'}, {'value': '4582', 'spread': '1324', 'groupId': 'OG003'}, {'value': '11347', 'spread': '1754', 'groupId': 'OG004'}, {'value': '12524', 'spread': '4756', 'groupId': 'OG005'}]}]}, {'title': 'Week 20: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '30', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '24', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '23', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3754', 'spread': '1132', 'groupId': 'OG000'}, {'value': '12757', 'spread': '4298', 'groupId': 'OG001'}, {'value': '4648', 'spread': '1528', 'groupId': 'OG002'}, {'value': '4698', 'spread': '1661', 'groupId': 'OG003'}, {'value': '10517', 'spread': '2031', 'groupId': 'OG004'}, {'value': '11425', 'spread': '3719', 'groupId': 'OG005'}]}]}, {'title': 'Week 24: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '21', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3613', 'spread': '813', 'groupId': 'OG000'}, {'value': '12626', 'spread': '3396', 'groupId': 'OG001'}, {'value': '4650', 'spread': '1461', 'groupId': 'OG002'}, {'value': '4767', 'spread': '1601', 'groupId': 'OG003'}, {'value': '10888', 'spread': '1576', 'groupId': 'OG004'}, {'value': '11625', 'spread': '5087', 'groupId': 'OG005'}]}]}, {'title': 'Week 28: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '17', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '4733', 'spread': '350', 'groupId': 'OG000'}, {'value': '12025', 'spread': '3229', 'groupId': 'OG001'}, {'value': '4300', 'spread': '1355', 'groupId': 'OG002'}, {'value': '4439', 'spread': '1446', 'groupId': 'OG003'}, {'value': '11753', 'spread': '2719', 'groupId': 'OG004'}, {'value': '11746', 'spread': '4752', 'groupId': 'OG005'}]}]}, {'title': 'Week 32: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '17', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '12162', 'spread': '2780', 'groupId': 'OG001'}, {'value': '4677', 'spread': '646', 'groupId': 'OG002'}, {'value': '4825', 'spread': '2429', 'groupId': 'OG003'}, {'value': '9840', 'spread': '3770', 'groupId': 'OG004'}, {'value': '12119', 'spread': '4062', 'groupId': 'OG005'}]}]}, {'title': 'Week 36: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '19', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '17', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '11289', 'spread': '2973', 'groupId': 'OG001'}, {'value': '4463', 'spread': '1444', 'groupId': 'OG002'}, {'value': '4144', 'spread': '1599', 'groupId': 'OG003'}, {'value': '11350', 'spread': '3439', 'groupId': 'OG004'}, {'value': '11192', 'spread': '5191', 'groupId': 'OG005'}]}]}, {'title': 'Week 44: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '17', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '11198', 'spread': '2749', 'groupId': 'OG001'}, {'value': '4507', 'spread': '1121', 'groupId': 'OG002'}, {'value': '3430', 'spread': '1346', 'groupId': 'OG003'}, {'value': '11570', 'spread': '2674', 'groupId': 'OG004'}, {'value': '11016', 'spread': '4277', 'groupId': 'OG005'}]}]}, {'title': 'Week 48: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '10', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '11797', 'spread': '2482', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG003'}, {'value': '11220', 'spread': '2464', 'groupId': 'OG004'}, {'value': '10740', 'spread': '2400', 'groupId': 'OG005'}]}]}, {'title': 'Follow-up: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '21', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '21', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '19', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '916', 'spread': '930', 'groupId': 'OG000'}, {'value': '2459', 'spread': '1529', 'groupId': 'OG001'}, {'value': '1330', 'spread': '887', 'groupId': 'OG002'}, {'value': '909', 'spread': '740', 'groupId': 'OG003'}, {'value': '1922', 'spread': '1628', 'groupId': 'OG004'}, {'value': '2192', 'spread': '1535', 'groupId': 'OG005'}]}]}, {'title': 'Follow-up: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '22', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '22', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '21', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '242', 'spread': '359', 'groupId': 'OG000'}, {'value': '494', 'spread': '427', 'groupId': 'OG001'}, {'value': '320', 'spread': '276', 'groupId': 'OG002'}, {'value': '226', 'spread': '236', 'groupId': 'OG003'}, {'value': '572', 'spread': '624', 'groupId': 'OG004'}, {'value': '1025', 'spread': '1523', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of JNJ-56136379 in currently not treated population administered as monotherapy or when co-administered with NA (ETV or TDF) was determined. As planned, the plasma concentration of JNJ-56136379 when co-administered with NA was determined separately for each NA treatment (ETV and TDF). Samples were analyzed using POP PK modeling.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "The PK analysis set included data for all participants with available plasma concentrations. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified timepoints."}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of JNJ-56136379 in Virologically Suppressed Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: JNJ-56136379 75 mg + NA (ETV)', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA (TDF)', 'description': 'Virologically suppressed participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg + NA (ETV)', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (0.5 mg ETV) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (ETV) for additional 24 weeks.'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg + NA (TDF)', 'description': 'Virologically suppressed participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA (300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Day 1: 0 hour', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due to below qualification limit (BQL) that is \\<10.0 ng/mL.', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that mean and standard deviation was not calculated due to below qualification limit (BQL) that is \\<10.0 ng/mL.', 'groupId': 'OG003'}]}]}, {'title': 'Day 1: 2 hour', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '17', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '857', 'spread': '238', 'groupId': 'OG000'}, {'value': '616', 'spread': '385', 'groupId': 'OG001'}, {'value': '2103', 'spread': '1400', 'groupId': 'OG002'}, {'value': '2083', 'spread': '1022', 'groupId': 'OG003'}]}]}, {'title': 'Week 1: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '2144', 'spread': '553', 'groupId': 'OG000'}, {'value': '2301', 'spread': '639', 'groupId': 'OG001'}, {'value': '5758', 'spread': '1081', 'groupId': 'OG002'}, {'value': '7280', 'spread': '2098', 'groupId': 'OG003'}]}]}, {'title': 'Week 2: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3193', 'spread': '1017', 'groupId': 'OG000'}, {'value': '3206', 'spread': '710', 'groupId': 'OG001'}, {'value': '8485', 'spread': '2269', 'groupId': 'OG002'}, {'value': '10077', 'spread': '2886', 'groupId': 'OG003'}]}]}, {'title': 'Week 4: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3689', 'spread': '1178', 'groupId': 'OG000'}, {'value': '3694', 'spread': '815', 'groupId': 'OG001'}, {'value': '10106', 'spread': '2838', 'groupId': 'OG002'}, {'value': '12167', 'spread': '4271', 'groupId': 'OG003'}]}]}, {'title': 'Week 8: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '19', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3917', 'spread': '1131', 'groupId': 'OG000'}, {'value': '3998', 'spread': '1376', 'groupId': 'OG001'}, {'value': '11295', 'spread': '3829', 'groupId': 'OG002'}, {'value': '13352', 'spread': '6072', 'groupId': 'OG003'}]}]}, {'title': 'Week 12: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4194', 'spread': '1279', 'groupId': 'OG000'}, {'value': '3813', 'spread': '945', 'groupId': 'OG001'}, {'value': '10404', 'spread': '4246', 'groupId': 'OG002'}, {'value': '12776', 'spread': '5191', 'groupId': 'OG003'}]}]}, {'title': 'Week 20: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '18', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3948', 'spread': '1151', 'groupId': 'OG000'}, {'value': '4134', 'spread': '1375', 'groupId': 'OG001'}, {'value': '10761', 'spread': '3980', 'groupId': 'OG002'}, {'value': '12432', 'spread': '4249', 'groupId': 'OG003'}]}]}, {'title': 'Week 24: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3989', 'spread': '957', 'groupId': 'OG000'}, {'value': '3836', 'spread': '1160', 'groupId': 'OG001'}, {'value': '10219', 'spread': '3370', 'groupId': 'OG002'}, {'value': '11542', 'spread': '4612', 'groupId': 'OG003'}]}]}, {'title': 'Week 28: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '16', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4259', 'spread': '1083', 'groupId': 'OG000'}, {'value': '3506', 'spread': '1032', 'groupId': 'OG001'}, {'value': '9959', 'spread': '2929', 'groupId': 'OG002'}, {'value': '11344', 'spread': '4482', 'groupId': 'OG003'}]}]}, {'title': 'Week 32: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3788', 'spread': '841', 'groupId': 'OG000'}, {'value': '3721', 'spread': '1088', 'groupId': 'OG001'}, {'value': '10189', 'spread': '3160', 'groupId': 'OG002'}, {'value': '12099', 'spread': '6301', 'groupId': 'OG003'}]}]}, {'title': 'Week 36: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3801', 'spread': '1170', 'groupId': 'OG000'}, {'value': '3535', 'spread': '964', 'groupId': 'OG001'}, {'value': '10036', 'spread': '2786', 'groupId': 'OG002'}, {'value': '12227', 'spread': '5396', 'groupId': 'OG003'}]}]}, {'title': 'Week 44: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3998', 'spread': '1139', 'groupId': 'OG000'}, {'value': '3784', 'spread': '1056', 'groupId': 'OG001'}, {'value': '9634', 'spread': '3707', 'groupId': 'OG002'}, {'value': '14853', 'spread': '7977', 'groupId': 'OG003'}]}]}, {'title': 'Week 48: 0 hours', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3918', 'spread': '1259', 'groupId': 'OG000'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG001'}, {'value': 'NA', 'spread': 'NA', 'comment': 'Here "NA" indicates that actual sampling time deviated too much from nominal scheduled sampling time. Therefore, data could not be estimated and analyzed at specific time point.', 'groupId': 'OG002'}, {'value': '15080', 'spread': '8060', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '621', 'spread': '607', 'groupId': 'OG000'}, {'value': '912', 'spread': '585', 'groupId': 'OG001'}, {'value': '1919', 'spread': '1359', 'groupId': 'OG002'}, {'value': '3190', 'spread': '4462', 'groupId': 'OG003'}]}]}, {'title': 'Follow-up: Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '15', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '89.8', 'spread': '102', 'groupId': 'OG000'}, {'value': '204', 'spread': '209', 'groupId': 'OG001'}, {'value': '389', 'spread': '384', 'groupId': 'OG002'}, {'value': '1066', 'spread': '2319', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of JNJ-56136379 in virologically suppressed population administered as monotherapy or when co-administered with NA (ETV or TDF) was determined. As planned, the plasma concentration of JNJ-56136379 when co-administered with NA was determined separately for each NA treatment (ETV and TDF). Samples were analyzed using POP PK modeling.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "The PK analysis set included data for all participants with available plasma concentrations. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified timepoints."}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-Associated Mutations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}, {'value': '17', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG001', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 3\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'OG002', 'title': 'Part B: JNJ-56136379 250 mg (Open Label)', 'description': 'Currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks..'}, {'id': 'OG003', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received 2\\*100 mg and 2\\*25 mg tablets of JNJ-56136379 plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'classes': [{'title': 'Emergence of mutations during 24 weeks (Week 0 to Week 24)', 'categories': [{'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Emergence of mutations between 25 and 48 weeks (Week 25 to Week 48)', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Emergence of mutations on NA treatment (Up to Follow-up Week 24)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From Week 0 to Week 24, From Week 25 to Week 48, Up to Follow-up Week 24', 'description': 'Number of participants with treatment-associated mutations were reported. Viral genome sequence analysis was performed to evaluate emergence of mutations associated with JNJ-56136379 considering 15 HBV core protein positions of interest. This outcome measure was planned to be analyzed for specified arms only.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "ITT population consisted of all participants who were randomized and received at least one dose of any study agent. If a participant received a study agent other than their randomly assigned study agent, participants were shown in the treatment arm as randomized. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure and 'n' (number analyzed) represents number of participants evaluable for the specified categories."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] less than (\\<) 60 International units per milliliter \\[IU/mL\\]) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received placebo matching to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'FG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received JNJ-56136379 75 mg (3\\*25 mg tablets) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'FG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received JNJ-56136379 75 mg (3\\*25 mg tablets) plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'FG003', 'title': 'Part B: JNJ-56136379 250 mg (Open-label)', 'description': 'Currently not treated participants received JNJ-56136379 250 mg (2\\*100 mg and 2\\*25 mg tablets) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'FG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received JNJ-56136379 250 mg (2\\*100 mg and 2\\*25 mg tablets) plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '43'}, {'groupId': 'FG001', 'numSubjects': '28'}, {'groupId': 'FG002', 'numSubjects': '66'}, {'groupId': 'FG003', 'numSubjects': '32'}, {'groupId': 'FG004', 'numSubjects': '63'}]}, {'type': 'Currently Not Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '22'}, {'groupId': 'FG001', 'numSubjects': '28'}, {'groupId': 'FG002', 'numSubjects': '33'}, {'groupId': 'FG003', 'numSubjects': '32'}, {'groupId': 'FG004', 'numSubjects': '33'}]}, {'type': 'Virologically Suppressed', 'achievements': [{'groupId': 'FG000', 'numSubjects': '21'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '33'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '30'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}, {'groupId': 'FG001', 'numSubjects': '24'}, {'groupId': 'FG002', 'numSubjects': '61'}, {'groupId': 'FG003', 'numSubjects': '28'}, {'groupId': 'FG004', 'numSubjects': '58'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '5'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '3'}]}, {'type': 'Disease Relapse', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}]}]}], 'preAssignmentDetails': 'As per planned analysis, the data for Part A Placebo + Nucleos(t)ide analog (NA) and Part B Placebo + NA arm was pooled into a single Placebo + NA arm for data interpretation since there was considerable time overlap in randomization between the two parts, with almost half of the participants of Part B recruited while Part A was still ongoing.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '43', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '66', 'groupId': 'BG002'}, {'value': '32', 'groupId': 'BG003'}, {'value': '63', 'groupId': 'BG004'}, {'value': '232', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Parts A and B: Pooled Placebo + Nucleos(t)Ide Analog (NA)', 'description': "Virologically suppressed (who were on entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\] for at least 12 months prior to screening and had hepatitis B virus \\[HBV\\] deoxyribonucleic acid \\[DNA\\] less than (\\<) 60 International units per milliliter \\[IU/mL\\]) or currently not treated (who didn't receive any HBV treatment 6 months prior to baseline) participants received placebo matching to JNJ-56136379 (75 milligrams \\[mg\\] or 250 mg) plus 1 tablet of NA (either 0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks."}, {'id': 'BG001', 'title': 'Part A: JNJ-56136379 75 mg (Open Label)', 'description': 'Currently not treated participants received JNJ-56136379 75 mg (3\\*25 mg tablets) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued treatment with JNJ-56136379 75 mg from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'BG002', 'title': 'Part A: JNJ-56136379 75 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received JNJ-56136379 75 mg (3\\*25 mg tablets) plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 75 mg treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'BG003', 'title': 'Part B: JNJ-56136379 250 mg (Open-label)', 'description': 'Currently not treated participants received JNJ-56136379 250 mg (2\\*100 mg and 2\\*25 mg tablets) once daily from Day 1 to Week 24 during the initial treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and received treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'BG004', 'title': 'Part B: JNJ-56136379 250 mg + NA', 'description': 'Virologically suppressed or currently not treated participants received JNJ-56136379 250 mg (2\\*100 mg and 2\\*25 mg tablets) plus 1 tablet of NA either (0.5 mg ETV or 300 mg TDF) once daily from Day 1 to Week 24 during treatment phase. Participants who completed the initial 24 weeks of treatment with a virologic response by Week 20 and without experiencing any safety concerns precluding continued JNJ-56136379 treatment from Week 24 to Week 48 in the treatment extension phase. Participants who did not participate in the treatment extension phase after Week 24 and those who completed the extension phase were followed up and continued treatment with only NA (either ETV or TDF) for additional 24 weeks.'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '41.6', 'spread': '9.53', 'groupId': 'BG000'}, {'value': '39.2', 'spread': '12.06', 'groupId': 'BG001'}, {'value': '40.3', 'spread': '11.12', 'groupId': 'BG002'}, {'value': '37.7', 'spread': '10.92', 'groupId': 'BG003'}, {'value': '40.5', 'spread': '10.99', 'groupId': 'BG004'}, {'value': '40.1', 'spread': '10.87', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}, {'value': '13', 'groupId': 'BG004'}, {'value': '70', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '29', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '46', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}, {'value': '50', 'groupId': 'BG004'}, {'value': '162', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '42', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '66', 'groupId': 'BG002'}, {'value': '32', 'groupId': 'BG003'}, {'value': '62', 'groupId': 'BG004'}, {'value': '230', 'groupId': 'BG005'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': 'Asian', 'measurements': [{'value': '18', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '35', 'groupId': 'BG002'}, {'value': '16', 'groupId': 'BG003'}, {'value': '30', 'groupId': 'BG004'}, {'value': '110', 'groupId': 'BG005'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '14', 'groupId': 'BG005'}]}, {'title': 'White', 'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}, {'value': '15', 'groupId': 'BG003'}, {'value': '30', 'groupId': 'BG004'}, {'value': '105', 'groupId': 'BG005'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'BELGIUM', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '11', 'groupId': 'BG005'}]}]}, {'title': 'CANADA', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '14', 'groupId': 'BG005'}]}]}, {'title': 'CHINA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '18', 'groupId': 'BG005'}]}]}, {'title': 'FRANCE', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '11', 'groupId': 'BG005'}]}]}, {'title': 'GERMANY', 'categories': [{'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}]}]}, {'title': 'ITALY', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}]}]}, {'title': 'JAPAN', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}]}]}, {'title': 'MALAYSIA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '8', 'groupId': 'BG005'}]}]}, {'title': 'POLAND', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '18', 'groupId': 'BG005'}]}]}, {'title': 'RUSSIAN FEDERATION', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '18', 'groupId': 'BG005'}]}]}, {'title': 'SOUTH KOREA', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}]}]}, {'title': 'SPAIN', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '12', 'groupId': 'BG005'}]}]}, {'title': 'TAIWAN', 'categories': [{'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '32', 'groupId': 'BG005'}]}]}, {'title': 'THAILAND', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '7', 'groupId': 'BG005'}]}]}, {'title': 'TURKEY', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '5', 'groupId': 'BG004'}, {'value': '23', 'groupId': 'BG005'}]}]}, {'title': 'UKRAINE', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}]}]}, {'title': 'UNITED KINGDOM', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}]}]}, {'title': 'UNITED STATES', 'categories': [{'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}]}]}, {'title': 'Hong Kong', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2019-08-02', 'size': 4952817, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-09-02T10:29', 'hasProtocol': True}, {'date': '2021-03-09', 'size': 4233579, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-09-02T10:29', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 232}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-02-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-10', 'dispFirstSubmitDate': '2020-09-02', 'completionDateStruct': {'date': '2020-08-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-10-24', 'studyFirstSubmitDate': '2017-11-29', 'dispFirstSubmitQcDate': '2022-10-24', 'resultsFirstSubmitDate': '2022-09-02', 'studyFirstSubmitQcDate': '2017-11-29', 'dispFirstPostDateStruct': {'date': '2022-11-17', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2022-11-17', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-10-24', 'studyFirstPostDateStruct': {'date': '2017-12-05', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2022-11-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-09-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels in Currently Not Treated Population at Week 24', 'timeFrame': 'Baseline and Week 24', 'description': "Change from baseline in HBsAg levels in currently not treated population at Week 24 based on Hepatitis B e Antigen (HBeAg) status was reported. Currently not treated population defined as participants who didn't receive any hepatitis B virus (HBV) treatment 6 months prior to baseline."}, {'measure': 'Change From Baseline in HBsAg Levels in Virologically Suppressed Population at Week 24', 'timeFrame': 'Baseline and Week 24', 'description': 'Change from baseline in HBsAg levels in virologically suppressed population at Week 24 based on HBeAg status was reported. Virologically suppressed population defined as participants who were on entecavir (ETV) or tenofovir disoproxil fumarate (TDF) for at least 12 months prior to screening and had HBV deoxyribonucleic acid (DNA) \\<60 IU/mL. This outcome measure was planned to be analyzed for specified arms only.'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With Treatment- Emergent Adverse Events (AEs)', 'timeFrame': 'Up to Week 48', 'description': 'An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Treatment-emergent AEs were AEs with onset during the treatment phase or that worsened since baseline.'}, {'measure': 'Number of Participants With Serious Adverse Events (SAEs)', 'timeFrame': 'Up to Week 80', 'description': 'A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs, Physical Examinations, Electrocardiogram (ECG), and Clinical Laboratory Tests', 'timeFrame': 'Up to Week 80', 'description': 'Number of participants with clinically significant changes in vital signs, physical examinations, ECG, and clinical laboratory tests (including hematology, blood biochemistry, blood coagulation, and urinalysis) were reported.'}, {'measure': 'Change From Baseline in HBsAg Levels in Currently Not Treated Population Over Time', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBsAg levels in currently not treated population based on HBeAg status was reported.'}, {'measure': 'Change From Baseline in HBsAg Levels in Virologically Suppressed Population Over Time', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBsAg levels in virologically suppressed population based on HBeAg status was reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Percentage of Participants With HBsAg Levels Less Than (<) 1,000 or <100 International Units Per Milliliter (IU/mL) in Currently Not Treated Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with HBsAg levels \\<1,000 or \\<100 IU/mL in currently not treated population based on their HBeAg status were reported.'}, {'measure': 'Percentage of Participants With HBsAg Levels <1,000 or <100 IU/mL in Virologically Suppressed Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with HBsAg levels \\<1,000 or \\<100 IU/mL in virologically suppressed population based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Percentage of Participants With Greater Than (>) 0.5 log10 IU/mL or >1 log10 IU/mL Reduction in HBsAg From Baseline in Currently Not Treated Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL or \\>1 log10 IU/mL reduction in HBsAg from baseline in currently not treated population based on their HBeAg status were reported.'}, {'measure': 'Percentage of Participants With >0.5 log10 IU/mL or >1 log10 IU/mL Reduction in HBsAg From Baseline in Virologically Suppressed Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL or \\>1 log10 IU/mL reduction in HBsAg from baseline in virologically suppressed population based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels in Currently Not Treated Population', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBV DNA levels in currently not treated population based on their HBeAg status was reported.'}, {'measure': 'Change From Baseline in HBV DNA Levels in Virologically Suppressed Population', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBV DNA levels in virologically supressed population based on their HBeAg status was reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Percentage of Participants With Undetectable HBV DNA Levels in Currently Not Treated Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with undetectable HBV DNA levels in currently not treated population based on their HBeAg status was evaluated.'}, {'measure': 'Percentage of Participants With Undetectable HBV DNA Levels in Virologically Suppressed Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with undetectable HBV DNA levels in virologically suppressed population based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Change From Baseline in HBeAg Levels in Currently Not Treated Population', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBeAg levels in HBeAg positive currently not treated population was reported.'}, {'measure': 'Change From Baseline in HBeAg Levels in Virologically Suppressed Population', 'timeFrame': 'Baseline up to Weeks 24, 48 and Follow-up Week 24', 'description': 'Change from baseline in HBeAg levels in HBeAg positive virologically suppressed population was reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Percentage of Participants With >0.5 log10 IU/mL and >1 log10 IU/mL Reduction in HBeAg From Baseline in Currently Not Treated Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL and \\>1 log10 IU/mL reduction in HBeAg from baseline in HBeAg positive currently not treated population was reported.'}, {'measure': 'Percentage of Participants With >0.5 log10 IU/mL and >1 log10 IU/mL Reduction in HBeAg From Baseline in Virologically Suppressed Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with \\>0.5 log10 IU/mL and \\>1 log10 IU/mL reduction in HBeAg from baseline in HBeAg positive virologically suppressed population was reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Percentage of Participants With HBsAg Seroclearance in Currently Not Treated Population', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroclearance in currently not treated population based on their HBeAg status were reported. Seroclearance at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at Week 24/48. Loss is defined as a baseline HBsAg with a repeat reactive, confirmed or positive result and a post-baseline assessment with a negative result. This outcome measure was planned to be analyzed at specified timepoints only.'}, {'measure': 'Percentage of Participants With HBsAg Seroclearance in Virologically Suppressed Population', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroclearance in virologically suppressed population based on their HBeAg status were reported. Seroclearance at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at Week 24/48. Loss is defined as a baseline HBsAg with a repeat reactive, confirmed or positive result and a post-baseline assessment with a negative result. This outcome measure was planned to be analyzed for specified arms and specific timepoints only .'}, {'measure': 'Percentage of Participants With HBsAg Seroconversion in Currently Not Treated Population', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroconversion in currently not treated population based on their HBeAg status were reported. Seroconversion at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at week 24/48 of the treatment and an appearance of Anti-HBs. This outcome measure was planned to be analyzed for specified timepoints only.'}, {'measure': 'Percentage of Participants With HBsAg Seroconversion in Virologically Suppressed Population', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with HBsAg seroconversion in virologically suppressed population based on their HBeAg status were reported. Seroconversion at Week 24/48 of the treatment defined as a confirmed loss of HBsAg at week 24/48 of the treatment and an appearance of Anti-HBs. This outcome measure was planned to be analyzed for specified arms and specified timepoints only.'}, {'measure': 'Percentage of Participants With Normalized Alanine Aminotransferase (ALT) Levels in Currently Not Treated Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with normalized ALT levels in currently not treated population, whose ALT levels were above upper limit of normal at baseline based on their HBeAg status were reported.'}, {'measure': 'Percentage of Participants With Normalized ALT Levels in Virologically Suppressed Population', 'timeFrame': 'Weeks 24, 48 and Follow-up Week 24', 'description': 'Percentage of participants with normalized ALT levels in virologically suppressed population, whose ALT levels were above upper limit of normal at baseline based on their HBeAg status were reported. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Percentage of Participants With Virological Breakthrough in Currently Not Treated Population', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with virological breakthrough in currently not treated population based on their HBeAg status was reported. Virological breakthrough defined as confirmed on treatment HBV DNA increase by \\>1 log10 from nadir level or confirmed on treatment level \\>200 IU/mL in participants who had HBV DNA level below the lower limit of quantification (LLOQ) of the HBV DNA assay.'}, {'measure': 'Percentage of Participants With Virological Breakthrough in Virologically Suppressed Population', 'timeFrame': 'Weeks 24 and 48', 'description': 'Percentage of participants with virological breakthrough in virologically suppressed population based on their HBeAg status was reported. Virological breakthrough defined as confirmed on treatment HBV DNA increase by \\>1 log10 from nadir level or confirmed on treatment level \\>200 IU/mL in participants who had HBV DNA level below the lower limit of quantification (LLOQ) of the HBV DNA assay. This outcome measure was planned to be analyzed for specified arms only.'}, {'measure': 'Plasma Concentrations of Entecavir [ETV] in Currently Not Treated Population', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of ETV administered as monotherapy or co-administered with JNJ-56136379 in currently not treated population was determined. As planned, plasma concentration of ETV co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.'}, {'measure': 'Plasma Concentrations of ETV in Virologically Suppressed Population', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of ETV administered as monotherapy or co-administered with JNJ-56136379 in virologically suppressed population was determined. As planned, plasma concentration of ETV co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.'}, {'measure': 'Plasma Concentrations of Tenofovir Disoproxil Fumarate (TDF) in Currently Not Treated Population', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of TDF administered as monotherapy or co-administered with JNJ-56136379 was determined. As planned, plasma concentration of TDF co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.'}, {'measure': 'Plasma Concentrations of TDF in Virologically Suppressed Population', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of TDF administered as monotherapy or co-administered with JNJ-56136379 was determined. As planned, plasma concentration of TDF co-administered with placebo was analyzed separately for Part A and Part B. Samples were analyzed using POP PK modeling.'}, {'measure': 'Plasma Concentrations of JNJ-56136379 in Currently Not Treated Population', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of JNJ-56136379 in currently not treated population administered as monotherapy or when co-administered with NA (ETV or TDF) was determined. As planned, the plasma concentration of JNJ-56136379 when co-administered with NA was determined separately for each NA treatment (ETV and TDF). Samples were analyzed using POP PK modeling.'}, {'measure': 'Plasma Concentrations of JNJ-56136379 in Virologically Suppressed Population', 'timeFrame': 'Day 1: 0 hours, 2 hours; Weeks 1, 2, 4, 8, 12, 20, 24, 28, 32, 36, 44, 48: 0 hours; Follow-up: Weeks 2 and 4', 'description': 'Plasma concentrations of JNJ-56136379 in virologically suppressed population administered as monotherapy or when co-administered with NA (ETV or TDF) was determined. As planned, the plasma concentration of JNJ-56136379 when co-administered with NA was determined separately for each NA treatment (ETV and TDF). Samples were analyzed using POP PK modeling.'}, {'measure': 'Number of Participants With Treatment-Associated Mutations', 'timeFrame': 'From Week 0 to Week 24, From Week 25 to Week 48, Up to Follow-up Week 24', 'description': 'Number of participants with treatment-associated mutations were reported. Viral genome sequence analysis was performed to evaluate emergence of mutations associated with JNJ-56136379 considering 15 HBV core protein positions of interest. This outcome measure was planned to be analyzed for specified arms only.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Hepatitis B']}, 'referencesModule': {'references': [{'pmid': '37385475', 'type': 'DERIVED', 'citation': 'Verbinnen T, Talloen W, Janssen HLA, Zoulim F, Shukla U, Vandenbossche JJ, Biermer M, De Meyer S, Lenz O. Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study. Antiviral Res. 2023 Aug;216:105660. doi: 10.1016/j.antiviral.2023.105660. Epub 2023 Jun 28.'}, {'pmid': '36697207', 'type': 'DERIVED', 'citation': 'Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, Janczewska E, Nahass RG, Bourgeois S, Buti M, Lampertico P, Lenz O, Verbinnen T, Vandenbossche J, Talloen W, Kalmeijer R, Beumont M, Biermer M, Shukla U. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 2023 Jul;72(7):1385-1398. doi: 10.1136/gutjnl-2022-328041. Epub 2023 Jan 25.'}, {'pmid': '32094138', 'type': 'DERIVED', 'citation': 'Berke JM, Dehertogh P, Vergauwen K, Mostmans W, Vandyck K, Raboisson P, Pauwels F. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02439-19. doi: 10.1128/AAC.02439-19. Print 2020 Apr 21.'}]}, 'descriptionModule': {'briefSummary': 'The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.', 'detailedDescription': 'The main study consists of 2-parts and each part will consist of 2 types of Chronic Hepatitis B-infected participant populations. Each part of the study will consist of screening phase (up to 8 weeks), treatment phase (24 weeks or 48 weeks, depending on treatment response), and post-treatment follow-up phase (24 weeks or 48 weeks, depending on treatment response). The duration of individual participation will be up to approximately 56 weeks (participants not eligible to continue treatment in extension phase), up to 80 weeks (participants continuing treatment in extension phase but not meeting treatment completion criteria), or up to 104 weeks (participants meeting treatment completion criteria). The safety and efficacy will be monitored throughout the study. In a separate substudy, at selected clinical sites, percutaneous core liver biopsy will be performed to evaluate changes of intrahepatic viral parameters.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Participants must have a body mass index (weight in kilogram (kg) divided by the square of height in meters) of 18.0 to 35.0 kilogram / square meter (kg/m\\^2), extremes included\n* Participants must have chronic hepatitis B virus infection (CHB) infection documented by: Serum hepatitis B surface antigen (HBsAg)-positive at screening and serum HBsAg- or hepatitis B virus (HBV) deoxyribonucleic acid (DNA)-positive at least 6 months prior to screening; Serum immunoglobulin M (IgM) anti- hepatitis B core-related (HBc) antibody negative at screening\n* In participants currently not being treated (Treatment Arms 1-2-3 and 6-7-8): Participants must not be receiving any CHB treatment at screening, that is, Have never received treatment with HBV antiviral medicines, including NAs or interferon (IFN) products, OR Have not been on treatment with HBV antiviral medicines, including nucleos(t)ide analog (NA)s or IFN products within 6 months prior to baseline (first intake of study drugs), and participants must be HBeAg-positive and have HBV DNA greater than or equal to (\\>=) 20,000 International Units Per Milliliter (IU/mL), OR be hepatitis B e antigen (HBeAg)-negative and have HBV DNA \\>=2,000 IU /mL at screening, and participants must have HBsAg greater than (\\>) 250 IU/mL at screening, and participants must have alanine aminotransferase (ALT) \\> upper limit of normal (ULN) and less than or equal to (\\<=) 5 \\* ULN at screening, determined in the central laboratory\n* In virologically suppressed participants (Treatment Arms 4-5 and 9-10): Participants must be virologically suppressed by current NA treatment (entecavir (ETV) or tenofovir disoproxil fumarate (TDF)) as defined by HBV DNA less than (\\<) 60 IU/mL at screening and at least 6 months prior to screening, and participants must be on the same NA treatment (ETV or TDF) and the same dose for \\>=12 months prior to screening, and participants must have HBsAg \\> 250 IU/mL at screening, and participants must have ALT \\<=2\\*ULN at screening\n* Participants must have: A liver biopsy result classified as Metavir F0-F2 within 1 year prior to screening or at the time of screening, OR FibroScan liver stiffness measurement \\<8.0 kilopascal (kPa) within 6 months prior to screening or at the time of screening\n\nExclusion Criteria:\n\nMain Study:\n\n* Participants who test positive for anti-hepatitis B surface (HBs) antibodies\n* Participants with current hepatitis A virus infection (confirmed by hepatitis A antibody immunoglobulin M \\[IgM\\]), hepatitis D virus (HDV) infection (confirmed by HDV antibody), hepatitis E virus infection (confirmed by hepatitis E antibody IgM), or human immunodeficiency virus (HIV)-1 or HIV-2 infection (confirmed by antibodies) at screening; participants with a history of or current HCV infection (confirmed by HCV antibody). Evidence of other active infection (bacterial, viral, fungal, including acute tuberculosis) deemed clinically relevant by the investigator that would interfere with study conduct or its interpretation will also lead to exclusion\n* Participants with any evidence of hepatic decompensation at any time point prior to or at the time of screening: Direct bilirubin \\>1.2\\* ULN, or International normalized ratio (INR) \\>1.5\\* ULN, or Serum albumin \\< lower limit of normal (LLN), or documented history or current evidence of variceal bleeding, ascites, or hepatic encephalopathy\n* Participants with a history of cardiac arrhythmia (example, extrasystoli, tachycardia at rest), history of risk factors for Torsades de Pointes syndrome (example, hypokalemia, family history of long QT syndrome) or history or other clinical evidence of significant or unstable cardiac disease (example, angina, congestive heart failure, myocardial infarction, diastolic dysfunction, significant arrhythmia, coronary heart disease, and/or clinically significant 12 lead electrocardiograms (ECGs) abnormalities), moderate to severe valvular disease, or uncontrolled hypertension at screening\n* Participants with contraindications to the use of ETV or TDF per local prescribing information\n\nSubstudy:\n\n* Presence of coagulopathy or hemoglobinopathy (including sickle cell disease, thalassemia)\n* Use of any anti-coagulant, anti-platelet, or non-steroidal anti-inflammatory drug medications from 10 days before until 5 days after each liver biopsy\n* Presence of ascites, focal liver lesions, and other findings that would be contraindications for liver biopsies'}, 'identificationModule': {'nctId': 'NCT03361956', 'briefTitle': 'An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection', 'organization': {'class': 'INDUSTRY', 'fullName': 'Janssen Sciences Ireland UC'}, 'officialTitle': 'A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection', 'orgStudyIdInfo': {'id': 'CR108410'}, 'secondaryIdInfos': [{'id': '2017-001110-29', 'type': 'EUDRACT_NUMBER'}, {'id': '56136379HPB2001', 'type': 'OTHER', 'domain': 'Janssen Sciences Ireland UC'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Part A: Arm 1 (JNJ-56136379 or NA) (open label)', 'description': 'Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir \\[ETV\\] or tenofovir disoproxil fumarate \\[TDF\\]), and enter the 24 week post treatment follow-up phase.', 'interventionNames': ['Drug: JNJ-56136379', 'Drug: NA (ETV or TDF)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part A: Arm 2 (Placebo+NA [ETV] or [TDF])', 'description': 'Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: Placebo', 'Drug: NA (ETV or TDF)']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])', 'description': 'Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: JNJ-56136379', 'Drug: NA (ETV or TDF)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part A: Arm 4 (Placebo + NA [ETV or TDF])', 'description': 'Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: Placebo', 'Drug: NA (ETV or TDF)']}, {'type': 'EXPERIMENTAL', 'label': 'Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])', 'description': 'Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: JNJ-56136379', 'Drug: NA (ETV or TDF)']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)', 'description': 'Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.', 'interventionNames': ['Drug: JNJ-56136379', 'Drug: NA (ETV or TDF)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part B: Arm 7 (placebo + NA [ETV or TDF])', 'description': 'Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: Placebo', 'Drug: NA (ETV or TDF)']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])', 'description': 'Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: JNJ-56136379', 'Drug: NA (ETV or TDF)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Part B: Arm 9 (placebo + NA [ETV or TDF])', 'description': 'Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: Placebo', 'Drug: NA (ETV or TDF)']}, {'type': 'EXPERIMENTAL', 'label': 'Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])', 'description': 'Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.', 'interventionNames': ['Drug: JNJ-56136379', 'Drug: NA (ETV or TDF)']}], 'interventions': [{'name': 'JNJ-56136379', 'type': 'DRUG', 'otherNames': ['JNJ-6379'], 'description': 'Participants will receive JNJ-56136379 tablet orally.', 'armGroupLabels': ['Part A: Arm 1 (JNJ-56136379 or NA) (open label)', 'Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])', 'Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])', 'Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])', 'Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)', 'Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Participants will receive matching placebo tablet orally.', 'armGroupLabels': ['Part A: Arm 2 (Placebo+NA [ETV] or [TDF])', 'Part A: Arm 4 (Placebo + NA [ETV or TDF])', 'Part B: Arm 7 (placebo + NA [ETV or TDF])', 'Part B: Arm 9 (placebo + NA [ETV or TDF])']}, {'name': 'NA (ETV or TDF)', 'type': 'DRUG', 'description': 'Participants will receive NA (ETV or TDF) tablet orally as per approved label.', 'armGroupLabels': ['Part A: Arm 1 (JNJ-56136379 or NA) (open label)', 'Part A: Arm 2 (Placebo+NA [ETV] or [TDF])', 'Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])', 'Part A: Arm 4 (Placebo + NA [ETV or TDF])', 'Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])', 'Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])', 'Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)', 'Part B: Arm 7 (placebo + NA [ETV or TDF])', 'Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])', 'Part B: Arm 9 (placebo + NA [ETV or TDF])']}]}, 'contactsLocationsModule': {'locations': [{'zip': '93301', 'city': 'Bakersfield', 'state': 'California', 'country': 'United States', 'facility': 'The Office of Franco Felizarta, MD', 'geoPoint': {'lat': 35.37329, 'lon': -119.01871}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Orlando Immunology Center', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '70112', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Tulane Medical Center (TMC)', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '08844', 'city': 'Hillsborough', 'state': 'New Jersey', 'country': 'United States', 'facility': 'I.D. Care, Inc.', 'geoPoint': {'lat': 40.4776, 'lon': -74.62682}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'NYU Hepatology Associates', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '15213', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'UPMC Center For Liver Diseases', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '2060', 'city': 'Antwerp', 'country': 'Belgium', 'facility': 'SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)', 'geoPoint': {'lat': 51.22047, 'lon': 4.40026}}, {'zip': '1200', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Cliniques Universitaires Saint-Luc', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '2650', 'city': 'Edegem', 'country': 'Belgium', 'facility': 'UZ Antwerpen', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': 'T2N 1N4', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'facility': 'University of Calgary', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'V6Z 2C7', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Vancouver ID Research and Care Centre Society', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'V6Z 2K5', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'GI Research Institute (G.I.R.I.)', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'H3H 2R9', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'McGill University Health Centre', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'ON M5G 2C4', 'city': 'Toronto', 'country': 'Canada', 'facility': 'Toronto General Hospital', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': '100034', 'city': 'Beijing', 'country': 'China', 'facility': "Peking University People's Hospital", 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100050', 'city': 'Beijing', 'country': 'China', 'facility': 'Beiijing Friendship Hospital, Capital Medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '130021', 'city': 'Changchun', 'country': 'China', 'facility': 'The First Hospital of Jilin University', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '510515', 'city': 'Guangzhou', 'country': 'China', 'facility': 'Nanfang Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '92110', 'city': 'Clichy', 'country': 'France', 'facility': 'Hôpital Beaujon', 'geoPoint': {'lat': 48.90018, 'lon': 2.30952}}, {'zip': '69004', 'city': 'Lyon', 'country': 'France', 'facility': 'Hopital de La Croix Rousse', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '75012', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Saint-Antoine', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '94800', 'city': 'Villejuif', 'country': 'France', 'facility': 'Hopital Paul Brousse', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}, {'zip': '10439', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '45122', 'city': 'Essen', 'country': 'Germany', 'facility': 'Universitatsklinikum Essen', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '60590', 'city': 'Frankfurt', 'country': 'Germany', 'facility': 'Universitätsklinikum Johann Wolfgang Goethe- Universität Frankfurt Medizinische Klinik 1', 'geoPoint': {'lat': 49.68333, 'lon': 10.53333}}, {'zip': '20099', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Asklepios Klinik St. Georg, Haus Lifi - Studien und Projekte GmbH', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'city': 'Hong Kong', 'country': 'Hong Kong', 'facility': 'Queen Mary Hospital, University of Hong Kong', 'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}, {'city': 'Shatin', 'country': 'Hong Kong', 'facility': 'The Chinese University of Hong Kong', 'geoPoint': {'lat': 22.38333, 'lon': 114.18333}}, {'zip': '20122', 'city': 'Milan', 'country': 'Italy', 'facility': 'Irccs Ospedale Maggiore Di Milano', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '20162', 'city': 'Milan', 'country': 'Italy', 'facility': 'ASST Grande Ospedale Metropolitano Niguarda', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '56124', 'city': 'Pisa', 'country': 'Italy', 'facility': 'Azienda Ospedaliero Universitaria Pisana', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'zip': '734-8551', 'city': 'Hiroshima', 'country': 'Japan', 'facility': 'Hiroshima University Hospital', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'zip': '180-8610', 'city': 'Musashino', 'country': 'Japan', 'facility': 'Musashino Red Cross Hospital', 'geoPoint': {'lat': 35.70611, 'lon': 139.55944}}, {'zip': '856-8562', 'city': 'Nagasaki', 'country': 'Japan', 'facility': 'National Hospital Organization Nagasaki Medical Center', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'zip': '467-8602', 'city': 'Nagoya', 'country': 'Japan', 'facility': 'Nagoya City University Hospital', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '565-0871', 'city': 'Suita-shi', 'country': 'Japan', 'facility': 'Osaka University Hospital'}, {'zip': '05460', 'city': 'Alor Star', 'country': 'Malaysia', 'facility': 'Hospital Sultanah Bahiyah', 'geoPoint': {'lat': 6.12104, 'lon': 100.36014}}, {'zip': '59100', 'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'University Malaya Medical Centre', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'zip': '41-500', 'city': 'Chorzów', 'country': 'Poland', 'facility': 'Szpital Specjalistyczny w Chorzowie', 'geoPoint': {'lat': 50.30582, 'lon': 18.9742}}, {'zip': '25-317', 'city': 'Kielce', 'country': 'Poland', 'facility': 'Wojewodzki Szpital Zespolony', 'geoPoint': {'lat': 50.87033, 'lon': 20.62752}}, {'zip': '41-400', 'city': 'Mysłowice', 'country': 'Poland', 'facility': 'ID Clinic', 'geoPoint': {'lat': 50.20745, 'lon': 19.16668}}, {'zip': '50-136', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'SP ZOZ Wroclawskie Centrum Zdrowia', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '630005', 'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Medical Center SibNovoMed LLC', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'zip': '443063', 'city': 'Samara', 'country': 'Russia', 'facility': 'Medical Company Hepatolog Ltd', 'geoPoint': {'lat': 53.20767, 'lon': 50.13553}}, {'zip': '355017', 'city': 'Stavropol', 'country': 'Russia', 'facility': 'Stavropol State Medical University', 'geoPoint': {'lat': 45.03442, 'lon': 41.9642}}, {'zip': '620102', 'city': 'Yekaterinburg', 'country': 'Russia', 'facility': 'Sverdlovsk Regional Clinical Hospital #1', 'geoPoint': {'lat': 56.85733, 'lon': 60.61529}}, {'zip': '49241', 'city': 'Busan', 'country': 'South Korea', 'facility': 'Pusan National University Hospital', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'zip': '03080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '03722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital, Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '8028', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hosp. Clinic I Provincial de Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '8035', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hosp. Univ. Vall D Hebron', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28034', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hosp. Univ. Ramon Y Cajal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '39008', 'city': 'Santander', 'country': 'Spain', 'facility': 'Hosp. Univ. Marques de Valdecilla', 'geoPoint': {'lat': 43.46589, 'lon': -3.80493}}, {'zip': '41013', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Virgen Del Rocio', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '80756', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Kaohsiung Medical University Chung-Ho Memorial Hospital', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40705', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Taichung Veterans General Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '70403', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '333', 'city': 'Taoyuan District', 'country': 'Taiwan', 'facility': 'Chang Gung Memorial Hospital Linkou Branch', 'geoPoint': {'lat': 24.9896, 'lon': 121.3187}}, {'zip': '10500', 'city': 'Bangkok', 'country': 'Thailand', 'facility': 'King Chulalongkorn Memorial Hospital', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '10700', 'city': 'Bangkok', 'country': 'Thailand', 'facility': 'Siriraj Hospital', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'zip': '50200', 'city': 'Chiang Mai', 'country': 'Thailand', 'facility': 'Chiang Mai University Hospital', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}, {'zip': '90110', 'city': 'Songkhla', 'country': 'Thailand', 'facility': 'Prince Of Songkla University', 'geoPoint': {'lat': 7.19882, 'lon': 100.5951}}, {'zip': '34098', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Istanbul University Cerrahpasa Medical Faculty', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34371', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Saglık Bilimleri University Şişli Trainig and Research Hospital,Department of Gastroenterology', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '35100', 'city': 'Izmir', 'country': 'Turkey (Türkiye)', 'facility': 'Ege University Medical of Faculty, Department of Gastroenterology', 'geoPoint': {'lat': 38.41273, 'lon': 27.13838}}, {'zip': '61080', 'city': 'Trabzon', 'country': 'Turkey (Türkiye)', 'facility': 'Karadeniz Teknik University Medical Faculty', 'geoPoint': {'lat': 41.005, 'lon': 39.72694}}, {'zip': '61000', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': 'Kharkiv National Medical University, Regional Clinical Infectious Hospital', 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '61039', 'city': 'Kharkiv', 'country': 'Ukraine', 'facility': "SE 'National institute therapy named L.T. Maloi NAMS of Ukraine'", 'geoPoint': {'lat': 49.98177, 'lon': 36.25475}}, {'zip': '65025', 'city': 'Odesa', 'country': 'Ukraine', 'facility': 'Odessa Regional Clinical Hospital', 'geoPoint': {'lat': 46.48572, 'lon': 30.74383}}, {'zip': '21021', 'city': 'Vinnytsia', 'country': 'Ukraine', 'facility': 'Vinnytsia City Clinical Hospital #1, Department of Infectious Diseases #1', 'geoPoint': {'lat': 49.2322, 'lon': 28.46871}}, {'zip': 'M8 5RB', 'city': 'Crumpsall', 'country': 'United Kingdom', 'facility': 'North Manchester General Hospital', 'geoPoint': {'lat': 53.51827, 'lon': -2.24447}}, {'zip': 'E1 1BB', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Grahame Hayton Unit', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'NE7 7DN', 'city': 'Newcastle upon Tyne', 'country': 'United Kingdom', 'facility': 'Newcastle upon Tyne Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'NG7 2UH', 'city': 'Nottingham', 'country': 'United Kingdom', 'facility': 'Nottingham University Hospitals NHS Trust', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}], 'overallOfficials': [{'name': 'Janssen Sciences Ireland UC Clinical Trial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Janssen Sciences Ireland UC'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Janssen Sciences Ireland UC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}